STOCKRETAIL-DRUG STORES AND PROPRIETARY STORESUpdated 2026-08-16
Here’s whether CVS HEALTH CORPORATION (CVS) is worth buying in 2026 —
based on weekly-updated price trend, RSI momentum, and return vs.
the S&P 500. Our current read: Neutral.
🔵
Neutral
Positives: trading above the 200-day MA (long-term uptrend intact); 50-day MA is rising (+1.16% over 10 days); strong 1-year return of +45.6%. Concerns: below the 50-day MA (medium-term momentum negative); RSI 29 — oversold. Currently 12.2% off its 52-week high. Score: +2/7.
CVS is holding above its long-term 200-day MA ($85.37) but has slipped below the 50-day MA ($102.28), pointing to short-term weakness in an otherwise intact trend. An RSI of 29.1 has dropped into oversold territory, which has historically preceded short-term bounces. The 1-year return of +45.6% compares to +20.4% for SPY (beat the market by 25.2%).
$10,000 invested 1 year ago→ $14,560 today
vs. S&P 500 (SPY) — same period beat market by 25.2%
1-Year Price Chart
Daily candles
MA-50MA-200UpDown
Signal Check
✓Above 200-day MA ($85.37)
✗Above 50-day MA ($102.28)
!RSI(14) neutral zone (30–70) — currently 29.1
✓Positive return (+45.6%)
!Within 10% of period high (−12.2%)
Period Range $97.16
$66.24$110.68
RSI (14) 29.1
0 · OversoldOverbought · 100
Key Metrics
Price$97.16
Period Return+45.6%
Period High$110.68
Period Low$66.24
Drawdown−12.2%
MA-50$102.28
MA-200$85.37
RSI (14)29.1
Avg Volume (30d)8.2M
vs. SPYbeat by 25.2%
Return Rank#327 of 1252
Trend Signals
Price is above the 200-day moving average ($85.37)
Price is below the 50-day moving average ($102.28)